A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
We evaluated the analgesic efficacy, safety and tolerability of a novel chemokine receptor 2 (CCR2) antagonist, AZD2423, in posttraumatic neuralgia. This was a double-blind, randomized, parallel-group, multicentre study. One hundred thirty-three patients with posttraumatic neuralgia were equally randomized to 28days' oral administration of 20mg AZD2423, 150mg AZD2423 or placebo. The primary efficacy variable was the change of average pain score from 5days at baseline to the last 5days of treatment, measured by a numerical rating scale (NRS, 0-10). The secondary efficacy measures included NRS worst pain score, patient global impression of change, pain interference on sleep and activity, and Neuropathic Pain Symptom Inventory (NPSI). The change of the NRS average pain score was not significantly different between treatment groups (AZD2423 20mg -1.54; AZD2423 150mg -1.53; placebo -1.44). There were trends towards larger reduction of NPSI total score and NPSI subscores for paroxysmal pain and paresthesia/dysesthesia by AZD2423 150mg compared to placebo. No other secondary efficacy variables differed between treatment groups. The frequency and type of adverse events for AZD2423 were similar to placebo. Increased plasma levels of chemokine ligand 2 and reduced mean levels of monocytes (-30% by AZD2423 150mg) suggested that the administrated doses of AZD2423 had interacted with the CCR2 target. The CCR2 antagonist AZD2423 demonstrated no efficacy on NRS average pain scores and most of the secondary pain variables. The NPSI data suggested possible effects on certain sensory components of pain. There were no major safety or tolerability concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Persistent postsurgical pain: risk factors and prevention
Kehlet, H., Jensen, T. S., & Woolf, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68700-x · Cited by 4,086
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523 · cited 1×
“The chemokine receptor 2 (CCR2) has been a target of interest for drug development in diverse therapeutic areas, primarily for treatment of chronic inflammatory diseases such as rheumatoid arthritis and multiple sclerosis [6,9,12,14].”
BackgroundDevelopment and validation of the Neuropathic Pain Symptom Inventory
Bouhassira, D., Attal, N., Fermanian, J., Alchaar, H., Gautron, M., Masquelier, E., Rostaing, S., Lanteri-Minet, M., Collin, E., Grisart, J., et al. (2004) · Pain · doi:10.1016/j.pain.2003.12.024 · Cited by 1,329
Self-citationTsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., & Charo, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29919 · Cited by 1,152 · cited 2×
“Inhibition of the transport of monocytes from the bone marrow to the blood has been suggested as a possible mechanism [18].”
Background
Cited by
Neuropathic Pain: From Mechanisms to Treatment
Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021) · Physiological Reviews · doi:10.1152/physrev.00045.2019 · Cited by 1,558
Glia and pain: Is chronic pain a gliopathy?
Ji, R.-R., Berta, T., & Nedergaard, M. (2013) · Pain · doi:10.1016/j.pain.2013.06.022 · Cited by 1,187
Emerging targets in neuroinflammation-driven chronic pain
Ji, R.-R., Xu, Z.-Z., & Gao, Y.-J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4334 · Cited by 1,101
Pathological pain and the neuroimmune interface
Grace, P. M., Hutchinson, M. R., Maier, S. F., & Watkins, L. R. (2014) · Nature Reviews Immunology · doi:10.1038/nri3621 · Cited by 932
Davis, K. D., Aghaeepour, N., Ahn, A. H., Angst, M. S., Borsook, D., Brenton, A., Burczynski, M. E., Crean, C., Edwards, R., Gaudilliere, B., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0362-2 · Cited by 496
Metadata
- Authors
- Kalliomäki, J., Attal, N., Jonzon, B., Bach, F. W., Huizar, K., Ratcliffe, S., Eriksson, B., Janecki, M., Danilov, A., & Bouhassira, D.
- Venue
- Pain
- Published
- 2013-05
- Volume
- 154
- Issue
- 5
- Pages
- 761-767
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W1972947543
- Cited by
- 76
- References
- 5
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.